| Literature DB >> 23882384 |
Abstract
When dosed appropriately on carefully chosen patients, methadone can be a very safe and effective choice in managing chronic pain. Many authors have discussed important issues surrounding patient selection, drug interactions, screening for QTc prolongation and monitoring. This article will focus on the dosing dilemma that exists after the patient is deemed an appropriate candidate for methadone and a conversion is necessary from another opioid. Despite many publications dedicated to addressing this challenging topic, there is no consensus on the most appropriate method for converting an opioid regimen to methadone. Given the lack of concrete guidance, clinicians in a community setting are likely to be faced with an increased challenge if there are no available pain specialists to provide clinical support. Common methods for converting morphine to methadone will be reviewed and two clinical patient scenarios used to illustrate the outcomes of applying the methods.Entities:
Keywords: conversion; equianalgesic; methadone; opioid rotation; pain management
Year: 2013 PMID: 23882384 PMCID: PMC3715153 DOI: 10.3402/jchimp.v2i4.19541
Source DB: PubMed Journal: J Community Hosp Intern Med Perspect ISSN: 2000-9666
Case examples
| Case 1: A 52-year-old Caucasian man with a history of esophageal cancer status post tracheostomy and PEG tube placement is receiving opioids for the management of chronic pain. His current course of pain medication is morphine 4 mg IV every 3 hours scheduled to avoid swallowing tablets and it has been effectively relieving his pain with minimal use of breakthrough opioid doses. The medical team is considering methadone liquid to provide long acting analgesia. |
| Case 2: A 66-year-old African-American woman with a history of severe diabetic peripheral neuropathy and low back pain. She has benefited from the last increase in her long acting opioids, however she has presented with myoclonus thought to be related to the increase in dose. Opioid rotation to methadone is considered, requiring a conversion from her current regimen, which is equivalent to 1,600 mg oral morphine. |
Summary of dosing ratios
| Ripamonti ( | ||||||
| Morphine dose (mg/day) | 30–90 | 90–300 | >300 | |||
| Morphine: methadone ratio | 4:1 | 6:1 | 8:1 | |||
| Ayonrinde ( | ||||||
| Morphine dose (mg/day) | <100 | 101–300 | 301–600 | 601–800 | 801–1,000 | >1,001 |
| Morphine: methadone ratio | 3:1 | 5:1 | 10:1 | 12:1 | 15:1 | 20:1 |
| Mercadante ( | ||||||
| Morphine dose (mg/day) | 30–90 | 90–300 | >300 | |||
| Morphine: methadone ratio | 4:1 | 8:1 | 12:1 | |||
| Methadone product information ( | ||||||
| Morphine dose (mg/day) | <100 | 100–300 | 300–600 | 600–1,000 | >1,000 | |
| Oral methadone as percent of total daily morphine dose | 20–30% | 10–20% | 8–12% | 5–10% | <5% | |
Fig. 1Summary of the Morley–Makin method.
Fig. 2Summary of the Friedman method.
Case 1 example
| Method | Ripamonti | Ayonrinde | Mercadante | Product information | Morley–Makin | Friedman |
|---|---|---|---|---|---|---|
| Morphine: methadone ratio | 6:1 | 3:1 | 8:1 | 20–30% | 10% q3h prn | 10% |
| Methadone daily dose | 16 mg | 32 mg | 12 mg | 19–29 mg | 10 mg q3h prn | 10 mg |
This is the initial dose offered for days 1–5, not the final calculated dose for day 6.
Fig. 3Comparison of methadone dosing methods. Friedman A represents conversions for patient <65 years of age and Friedman B represents conversions for patient >65 years of age.
Case 2 example
| Method | Ripamonti | Ayonrinde | Mercadante | Product information | Morley–Makin | Friedman |
|---|---|---|---|---|---|---|
| Morphine: methadone ratio | 8:1 | 20:1 | 12:1 | 5% | 10% q3h prn | 5% |
| Methadone daily dose | 200 mg | 80 mg | 133 mg | 80 mg | 30 mg q3h prn | 80 mg |
This is the initial dose offered for days 1–5, not the final calculated dose for day 6 (maximum dose recommended in this method).